Stocks Health care ANTX
NASDAQ · Health careAN2 Therapeutics, Inc. (ANTX)
It posted a net loss of $36.3M. At June 30, 2026 it held $44.3M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 11, 2026.
What AN2 Therapeutics, Inc. does
AN2 Therapeutics, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker ANTX.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | n/a | -$35.2M | -$1.16 | n/a |
| 2024 | n/a | -$51.3M | -$1.72 | n/a |
| 2023 | n/a | -$64.7M | -$2.74 | n/a |
| 2022 | n/a | -$41M | -$2.79 | n/a |
| 2022 | n/a | -$21.5M | -$10.64 | n/a |
Latest SEC filings
What AN2 Therapeutics, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- September 14, 2026
- August 11, 2026Quarterly report 10-Q · period to June 30, 2026
- August 11, 2026
- June 9, 2026
- June 4, 2026
- May 15, 2026Passive stake changed SCHEDULE 13G/A
- May 11, 2026Quarterly report 10-Q · period to March 31, 2026
- May 11, 2026
- April 22, 2026
- April 22, 2026Additional proxy material DEFA14A
Questions about ANTX
What does AN2 Therapeutics, Inc. do?
AN2 Therapeutics, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker ANTX.
Is AN2 Therapeutics, Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $36.3M.
When did AN2 Therapeutics, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 11, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the insider trade from September 16, 2026.
Similar companies
Follow ANTX
Get an email when AN2 Therapeutics, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Follow ANTX: get an email when it filesWhere the numbers come from
Financial figures are the values AN2 Therapeutics, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.